Bioventus Inc. (BVS) Stock Analysis
Verdict: HOLD
Ongoing M&A strategic review and cash flow deleveraging anchor valuation, but trimmed FY26 revenue guidance caps short-term upside.
Investment score: 64/100
Analysis as of
Is Bioventus Inc. stock worth reviewing? The TradeMates thesis
Bioventus demonstrates solid cash generation ($71.41M FCF in 2025) and deleveraging, supported by an active strategic review following an unsolicited takeover bid. However, top-line growth deceleration (3.14% revenue growth, FY26 revenue guidance updated to $590–595M) and post-earnings extended-hours pressure to $11.69 justify a Hold rating from the model perspective.
7-factor investment score
- Valuation: 72/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 78/100 (weight 10%)
- Risk-Adjusted Return: 68/100 (weight 15%)
Bioventus Inc. opportunities and risks
What speaks for BVS
- Ongoing Strategic Alternatives Review and Buyout Optionality
What speaks against BVS
- Top-Line Growth Stagnation and Revenue Guidance Trim
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BVS | 15.5x | 1.5x | 9.7x | 68.3% | 9.8% | 9.5% |
| NEOG | n/a | 2.9x | 30.3x | 47.4% | -6.3% | 1.9% |
| UFPT | 30.3x | 3.5x | 20.0x | 28.5% | 11.4% | 2.8% |
| XRAY | n/a | 0.5x | 43.5x | 49.5% | -15.0% | 7.2% |
| STAA | 311.8x | 3.7x | 34.4x | 76.2% | 1.1% | -0.5% |
| KIDS | n/a | 3.0x | 360.0x | 73.8% | -12.8% | 0.4% |
| Peer median | n/a | 3.0x | 34.4x | 49.5% | -6.3% | 1.9% |
Frequently asked questions about Bioventus Inc. (BVS)
Is BVS stock a good investment?
The TradeMates model rates Bioventus Inc. as HOLD with an investment score of 64/100. Bioventus demonstrates solid cash generation ($71.41M FCF in 2025) and deleveraging, supported by an active strategic review following an unsolicited takeover bid. However, top-line growth deceleration (3.14% revenue growth, FY26 revenue guidance updated to $590–595M) and post-earnings extended-hours pressure to $11.69 justify a Hold rating from the model perspective. This is algorithmic model output, not personal investment advice.
Is BVS stock a buy?
The TradeMates model verdict for BVS is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.